WHO ICTRP trial
Phase 2b Study to Evaluate Tulisokibart for Rheumatoid Arthritis
JPRN-jRCT2031250408 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2031250408 |
|---|---|
| Public title | Phase 2b Study to Evaluate Tulisokibart for Rheumatoid Arthritis |
| Scientific title | A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Rheumatoid Arthritis |
| Primary sponsor | Iwamoto Taro |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | USA;Japan;Canada;Japan;Chile;Japan;China;Japan;Columbia;Japan;Germany;Japan;Poland;Japan;South Korea;Japan;Spain;Japan;UK;Japan |
| Conditions | Rheumatoid Arthritis |
| Interventions | - High-dose tulisokibart group: Subcutaneous administration of high-dose tulisokibart in addition to methotrexate background therapy. - Medium-dose tulisokibart group: Subcutaneous administration of medium-dose tulisokibart in addition to… |
| Registration date | Feb 10, 2025 |
| Target size | 182 |
| Secondary IDs | NCT07176390 |
| Registry page | jrct.mhlw.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: